Table 1:
All | Naïve | Previously infected | |
---|---|---|---|
Dosing interval | |||
Days, median (IQR) | 69 (46–77) | 69 (36.5–77) | 66 (63–77) |
Days, range | 17–92 | 17–92 | 19–90 |
Weeks, median | 9.86 | 9.86 | 9.43 |
Days post V2 | |||
Median (IQR) | 30 (28–32) | 30 (28–32.8) | 29.5 (26–31.3) |
N | 108 | 83 | 25 |
Female, N (%) | 68 (63%) | 48 (58%) | 20 (80%) |
Male, N (%) | 40 (37%) | 35 (42%) | 5 (20%) |
Mean age | 35.14 | 34.74 | 36.44 |
Age in years, median (IQR) | 33 (24–42.5) | 33 (23–42.8) | 35 (28–42) |
Age range | 21–66 | 21–66 | 21–63 |
Infection status, N (%) | |||
Naïve | 83 (77%) | 83 (100%) | 0 (0%) |
Previous SARS-CoV-2 | 25 (23%) | 0 (0%) | 25 (100%) |
Ethnicity (self-reported*), N (%) | |||
White* | 90 (83%) | 68 (82%) | 22 (88%) |
Asian* | 10 (9%) | 8 (10%) | 2 (8%) |
Black* | 0 (0%) | 0 (0%) | 0 (0%) |
Other* | 5 (5%) | 4 (5%) | 1 (4%) |
Unreported | 3 (3%) | 3 (4%) | 0 (0%) |